Imatinib for gastrointestinal stromal tumours

Totman M
Record ID 32004000049
Authors' objectives:

This study aims to assess the clinical effects of imatinib alone or in combination with other treatments in people with gastrointestinal stromal tumour (GIST), compared with other systemic, surgical or supportive treatments.

Authors' recommendations: We found no evidence of effects of imatinib in people with resectable or benign GIST, many of whom have an excellent prognosis following resection. In people with unresectable or metastatic GIST, prognosis is reported as poor. We found no studies directly comparing imatinib versus other or no treatment. Conclusions about relative effectiveness and safety depend on historical comparisons with untreated populations and, therefore, have limited reliability. The identified studies suggest that imatinib is a promising therapy in people with advanced GIST, particularly if it is the case that prognosis is uniformly poor with other management. However, it is not clear how people should be selected for treatment, what dose and duration should be used and, most importantly, whether clinical benefits will outweigh risks. Further trials are currently underway, which may help to address these issues.7,8 Until further results become available, imatinib continues to be an experimental treatment for GIST, which should be given in the context of research protocols.
Authors' methods: Review
Project Status: Completed
URL for project:
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Antineoplastic Agents
  • Gastrointestinal Neoplasms
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Bazian Ltd, Wessex Institute for Health Research and Development
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.